Zacks Investment Research upgraded shares of Arch Therapeutics (OTCMKTS:ARTH) from a sell rating to a hold rating in a research note released on Tuesday morning.
According to Zacks, “Arch Therapeutics, Inc. is a medical device company. It develops products that make surgery and interventional care faster and safer by using an approach to stop bleeding, control leaking, and provide other advantages during surgery and trauma care. The Company’s lead product candidate includes AC5 (TM), a biocompatible synthetic peptide, to achieve hemostasis in minimally invasive and open surgical procedures. Arch Therapeutics, Inc. is headquartered in Wellesley, Massachusetts. “
ARTH has been the subject of a number of other reports. HC Wainwright set a $3.00 price target on shares of Arch Therapeutics and gave the stock a buy rating in a report on Tuesday, December 19th. ValuEngine downgraded shares of Arch Therapeutics from a hold rating to a sell rating in a report on Thursday, October 12th. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company. The company has an average rating of Buy and a consensus target price of $2.31.
Shares of Arch Therapeutics (ARTH) opened at $0.50 on Tuesday. The company has a market cap of $76.20, a PE ratio of -9.90 and a beta of 4.55. Arch Therapeutics has a twelve month low of $0.25 and a twelve month high of $0.89.
Arch Therapeutics Company Profile
Arch Therapeutics, Inc is a development-stage company. The Company operates as a biotechnology company. The Company focuses on developing products to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. The Company’s technology is based on a self-assembling peptide that creates a physical, mechanical barrier, which could be applied to seal organs or wounds that are leaking blood and other fluids.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Arch Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arch Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.